Bolt Biotherapeutics, Inc. Increase (Decrease) in Deferred Revenue
Bolt Biotherapeutics, Inc. (BOLT) reported Increase (Decrease) in Deferred Revenue of -$2.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $9.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$11.00K.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$1.88M, a 335.88% decline year-over-year.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$1.23M.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$4.64M.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$4.67M.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$3.61M.
- Bolt Biotherapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$2.16M, a 113.88% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.00K 10-Q · filed 2026-08-11 | -$1.88M derived: sum of 3 quarters · filed 2026-08-11 | -$3.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$11.00K 10-Q · filed 2026-05-12 | -$1.89M derived: sum of 2 quarters · filed 2026-05-12 | -$3.12M derived: sum of 3 quarters · filed 2026-05-12 | -$4.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.11M derived: sum of 2 quarters · filed 2026-03-12 | -$4.14M derived: sum of 3 quarters · filed 2026-08-11 | -$4.64M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.26M derived: sum of 2 quarters · filed 2026-08-11 | -$2.76M 10-Q · filed 2025-11-12 | -$1.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.53M 10-Q · filed 2026-08-11 | -$736.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$503.00K 10-Q · filed 2026-05-12 | $294.00K derived: sum of 2 quarters · filed 2026-05-12 | -$412.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.10M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $91.00K derived: sum of 2 quarters · filed 2026-03-12 | -$602.00K derived: sum of 3 quarters · filed 2026-03-12 | -$4.67M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.40M derived: sum of 2 quarters · filed 2025-11-12 | -$5.47M 10-Q · filed 2025-11-12 | -$6.22M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$693.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.76M 10-Q · filed 2025-08-14 | -$5.52M derived: sum of 3 quarters · filed 2025-08-14 | -$7.15M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$4.07M 10-Q · filed 2025-05-12 | -$4.83M derived: sum of 2 quarters · filed 2025-05-12 | -$6.46M derived: sum of 3 quarters · filed 2025-05-12 | -$6.99M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$2.39M derived: sum of 2 quarters · filed 2025-03-24 | -$2.92M derived: sum of 3 quarters · filed 2025-03-24 | -$3.61M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.17M derived: sum of 2 quarters · filed 2024-11-12 | -$2.85M 10-Q · filed 2024-11-12 | -$2.93M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$534.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.22M 10-Q · filed 2024-08-13 | -$1.30M derived: sum of 3 quarters · filed 2024-08-13 | -$2.51M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$683.00K 10-Q · filed 2024-05-14 | -$766.00K derived: sum of 2 quarters · filed 2024-05-14 | -$1.98M derived: sum of 3 quarters · filed 2024-05-14 | -$2.79M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$1.29M derived: sum of 2 quarters · filed 2024-03-21 | -$2.11M derived: sum of 3 quarters · filed 2024-03-21 | -$2.16M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.03M derived: sum of 2 quarters · filed 2023-11-09 | -$2.08M 10-Q · filed 2023-11-09 | -$2.42M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$819.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$870.00K 10-Q · filed 2023-08-07 | -$1.21M derived: sum of 3 quarters · filed 2023-08-07 | $3.34M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$51.00K 10-Q · filed 2023-05-11 | -$388.00K derived: sum of 2 quarters · filed 2023-05-11 | $4.16M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.21M derived: sum of 2 quarters · filed 2023-03-29 | $15.57M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $4.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $15.91M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $11.36M 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | -$67.00K derived: sum of 3 quarters · filed 2022-03-30 | -$69.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$67.00K derived: sum of 2 quarters · filed 2021-11-09 | -$69.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$69.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$2.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |